1. Home
  2. 研究案内
  3. 業績
Achievement

業績 Achievement

Achievement

業績　Achievement

研究案内

研究業績　2022年

  1. Honda S, Kohno T, Yamamoto M, Hirayama K, Kyo A, Hirabayashi M, Honda S. Early anatomical changes and association with photodynamic therapy induced acute exudative maculopathy in patients with macular diseases. Sci Rep. 2022;12(1):9105.
  2. Kyo A, Yamamoto M, Honda S. A case of angioid streaks that produced choroidal neovascularization after the onset of unilateral acute retinopathy in pseudoxanthoma elasticum. Am J Ophthalmol Case Rep. 2022;27:101591.
  3. Kyo A, Yamamoto M, Nagatomi Y, Kohno T, Honda S. Fundus white spots associated with graft-versus-host disease in the remission phase of acute myeloid leukemia. Am J Ophthalmol Case Rep. 2022;27:101609.
  4. Ueno Y, Honda S. A Case of Traumatic Medial Longitudinal Fasciculus Syndrome Whose Causal Lesion Was Detected by Thin-Section MRI with Susceptibility-Weighted Imaging. Case Rep Ophthalmol. 2022;13(2):368-373.
  5. Ishiguro N, Hayashi T, Yamawaki Y, Mizobuchi K, Yasukawa T, Honda S, Nakano T. Multimodal Imaging of Subfoveal Pachydrusen Containing a Blood Flow Signal. Case Rep Ophthalmol Med. 2022;2022:5680913.
  6. Tagami M, Kakehashi A, Katsuyama-Yoshikawa A, Misawa N, Sakai A, Wanibuchi H, Azumi A, Honda S. FOXP3 and CXCR4-positive regulatory T cells in the tumor stroma as indicators of tumor immunity in the conjunctival squamous cell carcinoma microenvironment. PLoS One. 2022;17(3):e0263895.
  7. Tagami M, Misawa N, Noma-Ishikura S, Honda S, Kase S, Honda S. Epidermal growth factor receptor expression in a case of focal nodular gliosis of the retina. Retin Cases Brief Rep. 2022;16(3):375-378.
  8. Mori Y, Miyake M, Hosoda Y, Miki A, Takahashi A, Muraoka Y, Miyata M, Sato T, Tamura H, Ooto S, Yamada R, Yamashiro K, Nakamura M, Tajima A, Nagasaki M, Honda S, Tsujikawa A. Genome-wide Survival Analysis for Macular Neovascularization Development in Central Serous Chorioretinopathy Revealed Shared Genetic Susceptibility with Polypoidal Choroidal Vasculopathy. Ophthalmology. 2022:S0161-6420(22)00306-2.
  9. Sakai A, Tagami M, Misawa N, Yamamoto M, Kohno T, Honda S. Safety and efficacy of 27-gauge transconjunctival vitrectomy for the diagnosis of posterior uveitis or pan uveitis of unknown origin. BMC Ophthalmol. 2022;22(1):178.
  10. Kojima Y, Misawa N, Yamamoto T, Honda S. Intraoperative alteration in the vital signs of diabetic patients during cataract surgery with local anesthesia. PLoS One. 2022;17(3):e0265135.
  11. Tagami M, Honda S, Azumi A. Insights into Current Management Strategies for Dysthyroid Optic Neuropathy: A Review. Clin Ophthalmol. 2022;16:841-850.

研究業績　2021年

  1. Honda S, Yanagi Y, Koizumi H, Chen Y, Tanaka S, Arimoto M, Imai K. Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan. Sci Rep. 2021;11(1):13152.
  2. Kyo A, Yamamoto M, Hirayama K, Kohno T, Theisen-Kunde D, Brinkmann R, Miura Y, Honda S. Factors affecting resolution of subretinal fluid after selective retina therapy for central serous chorioretinopathy. Sci Rep. 2021;11(1):8973.
  3. Hirayama K, Yamamoto M, Kohno T, Kyo A, Theisen-Kunde D, Brinkmann R, Miura Y, Honda S. Selective retina therapy (SRT) for macular serous retinal detachment associated with tilted disc syndrome. Graefes Arch Clin Exp Ophthalmol. 2021;259(2):387-393.
  4. Tagami M, Misawa N, Sakai A, Honda S. Two Cases of Extremely High-IL-6 Pan-uveitis with Subretinal Exudation and Cell Migration. Ocul Immunol Inflamm. 2021 May 12:1-5.
  5. Misawa N, Tagami M, Sakai A, Kohno T, Honda S. Visual outcomes and choroidal thickness associated with human leukocyte antigen DRB1*04 in unclassifiable uveitis in Japanese patients. BMC Ophthalmol. 2021;21(1):457.
  6. Tagami M, Kakehashi A, Sakai A, Misawa N, Katsuyama-Yoshikawa A, Wanibuchi H, Azumi A, Honda S. Expression of thrombospondin-1 in conjunctival squamous cell carcinoma is correlated to the Ki67 index and associated with progression-free survival. Graefes Arch Clin Exp Ophthalmol. 2021;259(10):3127-3136.
  7. 山本 学, 安川 力, 高橋 寛二.　抗VEGF治療セミナー　光干渉断層血管撮影の加齢黄斑変性における活用法　あたらしい眼科2021;38(12):1483-1484.
  8. 本田 茂.【黄斑の最新レーザー診断、検査、治療】眼科における光線力学的療法(PDT)の歴史と現状 日本レーザー医学会誌2021;42(2):78-88.
  9. 平山 公美子, 山本 学.【黄斑の最新レーザー診断、検査、治療】網膜疾患に対する選択的網膜色素上皮レーザー治療(Selective Retina Therapy、SRT)の臨床研究 日本レーザー医学会誌2021;42(2):89-95.
  10. 本田 聡, 山本 学, 中尾 拓貴, 本田 茂.　リネゾリドによる視神経症が疑われた多剤耐性肺結核の1例　臨床眼科2021;75(4):508-513.

研究業績　2020年

  1. Tagami M, Honda S, Azumi A. Preoperative clinical factors and visual outcomes following orbital decompression with dysthyroid optic neuropathy. BMC Ophthalmol. 2020;20:30.
  2. Tagami M, Misawa N, Noma-Ishikura S, Honda S, Kase S, Honda S. Epidermal Growth factor receptor expression in a case of focal nodular gliosis of the Retina. Retin Cases Brief Rep. 2020 Feb 13. doi: 10.1097/ICB.0000000000000987. Epub ahead of print. PMID: 32058355.
  3. Sakai A, Tagami M, Kakehashi A, Katsuyama-Yoshikawa A, Misawa N, Wanibuchi H, Azumi A, Honda S. Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment. PLoS One. 2020;15:e0238120.
  4. Misawa N, Tagami M, Sakai A, Kohno T, Honda S. Rapid regression of scleral melting associated with tumor necrosis factor-α in a case of surgically induced necrotizing scleritis. Case Rep Ophthalmol. 2020;11:418-422.
  5. Yamamoto M, Miura Y, Kyo A, Hirayama K, Kohno T, Theisen-Kunde D, Brinkmann R, Honda S. Selective retina therapy for subretinal fluid associated with choroidal nevus. Am J Ophthalmol Case Rep. 2020;19:100794.
  6. Yamamoto M, Miura Y, Hirayama K, Kohno T, Kabata D, Theisen-Kunde D, Brinkmann R, Honda S. Predictive factors of outcome of selective retina therapy for diabetic macular edema. Int Ophthalmol. 2020;40:1221-1232.
  7. Tamachi T, Kohno T, Yamamoto M, Hirayama K, Kyo A, Ueda N, Hirabayashi M, Shiraki K, Honda S. One-year results of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmol Ther. 2020;9:1069-1082.
  8. Nishimura S, Sugimoto A, Kushiyama S, Togano S, Kuroda K, Yamamoto Y, Yamauchi M, Sumi T, Kaneda H, Kawaguchi T, Kato M, Tagami M, Oebisu N, Hoshi M, Kimura K, Kubo S, Muguruma K, Takashima T, Ohira M, Yashiro M. Clinical benefit for clinical sequencing using cancer panel testing. PLoS One. 2021;16:e0247090.
  9. Hayashida M, Miki A, Nakai S, Matsumiya W, Imai H, Kusuhara S, Honda S, Nakamura M. Genetic factors associated with treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy. Mol Vis. 2020;26:505-509.
  10. Hayashida M, Miki A, Honda S, Nakamura M. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy. Photodiagnosis Photodyn Ther. 2020;31:101955.
  11. 田町 知子, 河野 剛也, 山本 学, 平山 公美子, 居 明香, 平林 倫子, 本田 茂. 初回と2回目の光線力学的療法後に異なる早期反応を示したポリープ状脈絡膜血管症の一例. 眼科臨床紀要2020;1:802-806.
  12. 西野 智之, 山本 学, 河野 剛也, 本田 茂. 残存水晶体嚢が再発性硝子体出血の原因と思われた1例. あたらしい眼科2020;37:89-93.
  13. 本田 茂.【眼科救急疾患2020】網膜硝子体　原因不明の硝子体出血. 眼科 2020;62:1277-1281.
  14. 平山 公美子.【すべて見せます!患者説明・同意書マニュアル】AMD　蛍光眼底造影検査. 臨床眼科2020;74:267-269.
  15. 山本 学. 内科医・眼科医連携のピットフォール　網膜症以外に注意しなければいけない眼科疾患. 糖尿病合併症2020;34:38-41.
  16. 本田 茂. 知っておくと得をするRetina百科(第16回)　光線力学療法(PDT)の現状と使い方. Retina Medicine 2020;9:90-92.

研究業績　2019年

  1. Hosoda Y, Miyake M, Schellevis RL, Boon CJF, Hoyng CB, Miki A, Meguro A, Sakurada Y, Yoneyama S, Takasago Y, Hata M, Muraoka Y, Nakanishi H, Oishi A, Ooto S, Tamura H, Uji A, Miyata M, Takahashi A, Ueda-Arakawa N, Tajima A, Sato T, Mizuki N, Shiragami C, Iida T, Khor CC, Wong TY, Yamada R, Honda S, de Jong EK, Hollander AID, Matsuda F, Yamashiro K, Tsujikawa A. Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central serous chorioretinopathy. Commun Biol. 2019;2:468.
  2. Misawa N, Tagami M, Kohno T, Honda S. Correlation between visual acuity and human leukocyte antigen DRB1*04 in patients with Vogt-Koyanagi-Harada disease. BMC Ophthalmol. 2019;19:214.
  3. Sakurada Y, Tanaka K, Miki A, Matsumoto H, Kawamura A, Mukai R, Akiyama H, Honda S, Mori R, Iijima H. Clinical characteristics of cuticular drusen in the Japanese population. Jpn J Ophthalmol. 2019;63:448-456.
  4. Nakai S, Matsumiya W, Miki A, Honda S, Nakamura M. Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2019;63:389-395.
  5. Hirayama K, Yamamoto M, Kohno T, Teisen-kunde D, Brinkmann R, Miura Y, Honda S. Change in the Thickness of Retinal Layers after Selective Retina Therapy (SRT) in Patients with Central Serous Chorioretinopathy. Osaka City Medical Journal. 2019;65:55-63.
  6. Nakai S, Matsumiya W, Keiko O, Miki A, Nakamura M, Honda S. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2019;63:100-108.
  7. Terasaki H, Shiraki K, Ohji M, Metzig C, Schmelter T, Zeitz O, Sowade O, Kobayashi M, Vitti R, Berliner A, Shiraga F. Efficacy and safety outcomes of intravitreal aflibercept focusing on patients with diabetic macular edema from japan. Retina. 2019;39:938-947.

研究業績　2018年

  1. Takahashi K, Ohji M, Terasaki H, Honda S, Margaron P, Guerin T, Yuzawa M. Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study. Clin Ophthalmol. 2018;12:1789-1799.
  2. Miki A, Sakurada Y, Tanaka K, Semba K, Mitamura Y, Yuzawa M, Tajima A, Nakatochi M, Yamamoto K, Matsuo K, Imoto I, Honda S. Genome-Wide Association Study to Identify a New Susceptibility Locus for Central Serous Chorioretinopathy in the Japanese Population. Invest Ophthalmol Vis Sci. 2018;59:5542-5547.

研究業績　2017年以前

  1. Yasui A, Yamamoto M, Hirayama K, Shiraki K, Theisen-Kunde D, Brinkmann R, Miura Y, Kohno T. Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:243-254.
  2. Nakai S, Honda S, Matsumiya W, Miki A, Nakamura M. ARMS2 variants may predict the 3-year outcome of photodynamic therapy for wet age-related macular degeneration. Mol Vis. 2017;23:514-519.
  3. Ikeda N, Ikeda T, Kohno T. Traumatic myopia secondary to ciliary spasm after blunt eye trauma and reconsideration of its pathogenesis. Graefes Arch Clin Exp Ophthalmol. 2016;254:1411-7.
  4. Nagasaki J, Nishimoto M, Nakamae H, Nakane T, Koh H, Yoshimoto K, Shiraki K, Hino M. Optic Neuritis Associated with Myelodysplastic Syndrome Accompanied by Eosinophilic Crisis. Intern Med. 2015;54:2241-4.
  5. Yamaguchi M, Ataka S, Shiraki K. Subretinal fluid drainage via original retinal breaks for rhegmatogenous retinal detachment. Can J Ophthalmol. 2014;49:256-60.
  6. Iwami H, Pruessner J, Shiraki K, Brinkmann R, Miura Y. Protective effect of a laser-induced sub-lethal temperature rise on RPE cells from oxidative stress. Exp Eye Res. 2014;124:37-47.
  7. Matsumiya W, Honda S, Yanagisawa S, Miki A, Nagai T, Tsukahara Y. Evaluation of clinical and genetic indicators for the early response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics. 15:833-43, 2014.
  8. Yoshida Y, Kohno T, Yamamoto M, Yoneda T, Iwami H, Shiraki K. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2013;57:283-93.
  9. Matsuda K, Yokoyama T, Matsumoto H, Yamashita R, Kohno T, Shiraki K. [Relationship between birth month and corneal radius or axial length]. Nippon Ganka Gakkai Zasshi. 2013;117:102-9.
  10. Honda S, Bessho H, Kondo N, Kusuhara S, Tsukahara Y, Negi A. Positive association of CD36 gene variants with the visual outcome of photodynamic therapy in polypoidal choroidal vasculopathy. Mol Vis. 2012;18:2796-804.
  11. Ataka S, Yamaguchi M, Kohno T, Shiraki K. A case of persistent hypotony following 23-gauge vitrectomy. Int Ophthalmol. 2012;32:177-81.
  12. Tano Y, Ohji M; EXTEND-I Study Group. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmol. 2011;89:208-17.
  13. Bessho H, Honda S, Kondo N, Negi A. The association of ARMS2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Mol Vis. 17:977-982, 2011.
  14. Iwami H, Kohno T, Yamamoto M, Kaida M, Miki N, Ataka S, Shiraki K. Progression of cataracts following photodynamic therapy combined with intravitreous triamcinolone injection in cases of age-related macular degeneration. Osaka City Med J. 2011;57:49-57.
  15. Yamaguchi M, Yokoyama T, Shiraki K. Surgical procedure for correcting globe dislocation in highly myopic strabismus. Am J Ophthalmol. 2010;149:341-346.e2
  16. Nomura Y, Nakakura S, Moriwaki M, Takahashi Y, Shiraki K. Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma. Clin Ophthalmol. 2010;4:643-7.
  17. Tano Y, Ohji M; EXTEND-I Study Group. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol. 2010;88:309-16.

教室紹介
About Us

研究案内
For Physicians

診療案内
For Patients

研修・入局案内
For Students And Residents

プライバシーポリシー +81-06-6645-3867 Copyright © 2018- Department of Ophthalmology and Visual Sciences, Osaka Metropopolitan University Graduate School of Medicine. All Rights Reserved.